Abstract
Langerhans cell histiocytosis is a rare disease consistent in its histologic characteristics, but variable in both phenotypic presentation and prognosis. Classically, a soft tissue mass with adjacent bony destruction is often present that shows a histologic monoclonal proliferation of cells positive for CD1a, S100, and langerin (CD207). Pathognomonic Birbeck granules may be seen on transmission electron microscopy. In this review, the diagnosis, etiologies, treatments, and, most importantly, the classification schemes are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Herwig MC, Wojno T, Zhang Q, Grossniklaus HE. Langerhans cell histiocytosis of the orbit: five clinicopathologic cases and review of the literature. Surv Ophthalmol. 2013;58:330–40.
Giovannetti F, Giona F, Ungari C, et al. Langerhans cell histiocytosis with orbital involvement: our experience. J Oral Maxillofac Surg. 2009;67:212–6.
Margo CE, Goldman DR. Langerhans cell histiocytosis. Surv Ophthalmol. 2008;53:332–58.
Harris GJ. Langerhans cell histiocytosis of the orbit: a need for interdisciplinary dialogue. Am J Ophthalmol. 2006;141:374–8.
Harris GJ, Woo KI. Is unifocal Langerhans-cell histiocytosis of the orbit a “CNS-Risk” lesion? Pediatr Blood Cancer. 2004;43(3):298–9, author reply 300–1.
Stalemark H, Laurencikas E, Karis J, et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. 2008;51(1):76–81.
Maccheron LJ, McNab AA, Elder J, et al. Ocular adnexal Langerhans cell histiocytosis clinical features and management. Orbit. 2006;25(3):169–77.
Cheung N, Selva D, McNab AA. Orbital Langerhans cell histiocytosis in adults. Ophthalmology. 2007;114:1569–73.
Cochrane LA, Prince M, Clarke K. Langerhans’ cell histiocytosis in the paediatric population: presentation and treatment of head and neck manifestations. J Otolaryngol. 2003;32(1):33–7.
Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56:451–61.
Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12(2):327–38.
Grois N, Flucher-Wolfram B, Heitger A, et al. Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Med Pediatr Oncol. 1995;24(4):248–56.
Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42(5):438–44.
Grois N, Potschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–33.
Grois N, Prayer D, Prosch H, et al. Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43(1):59–65.
Minov M, Grois N, McClain K, et al. Histiocyte society evaluation and treatment guidelines. http://www.histiocytesociety.org/document.doc?id=290. Apr 2009.
Compliance with Ethical Standards
Zachary D. Pearce, Adam S. Hassan, and Hakan Demirci declare that they have no conflict of interest. No human studies were carried out by the authors for this article. No animal studies were carried out by the authors for this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pearce, Z.D., Demirci, H., Hassan, A.S. (2015). Langerhans Cell Histiocytosis. In: Demirci, H. (eds) Orbital Inflammatory Diseases and Their Differential Diagnosis. Essentials in Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46528-8_8
Download citation
DOI: https://doi.org/10.1007/978-3-662-46528-8_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46527-1
Online ISBN: 978-3-662-46528-8
eBook Packages: MedicineMedicine (R0)